Eli Lilly's Retatrutide Shows Up to 28% Weight Loss in Phase 3; Foundayo Delivers Strong A1C Reduction
Summary
Eli Lilly announced compelling Phase 3 clinical trial results for its highly anticipated obesity and diabetes drug, Retatrutide, demonstrating up to 28% weight loss and approximately 2 points A1C reduction. This new data reinforces the drug's potential as a major pipeline asset. Additionally, the company reported specific long-term data for its recently FDA-approved oral GLP-1, Foundayo, showing a 2.2% A1C reduction at 52 weeks, outperforming oral semaglutide and dapagliflozin. This follows the FDA approval of Foundayo in April and further solidifies Eli Lilly's dominant position in the metabolic disease market. An FDA filing for Foundayo is planned by the end of Q2, which could expand its market presence.
At the time of this announcement, LLY was trading at $1,155.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.